Common drug interactions leading to adverse drug events in the intensive care unit: Management and pharmacokinetic considerations

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  Papadopoulos, John ^a,b,c   Smithburger, Pamela L ^d  

^a Arnold and Marie Schwartz College of Pharmacy   (United States)

^b Pharmacotherapy   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Drug interactions; Drug drug interactions; Drug disease state interactions; Drug laboratory interactions; Inducers; Inhibitors; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALUMINUM HYDROXIDE; AMIODARONE; BENZATROPINE; BISACODYL; CALCIUM CARBONATE; CARBAMAZEPINE; CHLORPROMAZINE; CIPROFLOXACIN; CISAPRIDE; CYCLOSPORIN; DIAZEPAM; DIPHENHYDRAMINE; DIPYRIDAMOLE; ERYTHROMYCIN; FELODIPINE; FUROSEMIDE; HYOSCYAMINE; INDOMETACIN; ITRACONAZOLE; MACROGOL; METOCLOPRAMIDE; NICARDIPINE; NIFEDIPINE; PROTON PUMP INHIBITOR; RIFAMPICIN; TARTARIC ACID; TETRACYCLINE; UNINDEXED DRUG;

ADVERSE DRUG REACTION; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; GRAPEFRUIT JUICE; HUMAN; INTENSIVE CARE UNIT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

EID: 77953030873     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de0acf     Document Type: Article

References (132)

1. Rivkin A: Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64: 1840-1843
2. Hanlon JT, Artz MB, Pieper CF, et al: Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004; 38:9-14
3. Reynolds JC: The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12(Suppl 2): S54-S63
4. Patterson TF, Peters J, Levine SM, et al: Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40:2217-2220
5. Product Information: Sporanox, itraconazole. Janssen Pharmaceutical, Titusville, NJ, 1999
6. Bruggeman RJM, Alffenaar JWC, Blijlevens NMA, et al: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-1458
7. Derendorf H, VanderMaelen CP, Brickl RS, et al: Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 2005; 45:845-850
8. Product Information: Aggrenox' aspirin/ extended-release dipyridamole. BoeringerIngelheim Pharmaceuticals, Ridgefield, CT, 2009
9. Romac DR, Albertson TE: Drug interactions in the intensive care unit. Clin Chest Med 1999; 20:385-399
10. Boucher BA, Wood GC, Swanson JM: Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22:255-271
11. Heyland DK, Tougas G, King D, et al: Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996; 22:1339-1344
12. Hansten PD, Horn JR: Hansten and Horn's Drug Interactions Analysis and Management. Vancouver, WA, Applied Therapeutics, 1997, pp 481-521
13. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al: The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 1987; 19:1730-1733 (Pubitemid 17026995)
14. Elbarbry FA, Marfleet T, Shoker AS: Drug-drug interactions with immunosuppressive agents: Review of the invitro functional assays and role of cytochrome P450 emzymes. Transplantation 2008; 85: 1222-1229
15. Kolars JC, Schmiedlin-Ren P. Schuetz JD, et al: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878
16. Kim YH, Yoon YR, Kim YW, et al: Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Tranplant Proc 1998; 30:3570-3572
17. Libersa CC, Brique SA, Motte KB, et al: Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49:373-378
18. Bailey DG, Spence JD, Munoz C, et al: Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337:268-269
19. Chapron DJ, Kramer PA, Mariano SL, et al: Effect of calcium and antacids on phenytoin bioavailability. Arch Neurol 1979; 36: 436-438
20. Longe R, Smith O: Phenytoin interaction with an oral feeding results in loss of seizure control. J Am Geriatr Soc 1988; 36: 542-544
21. Frost RW, Lasseter KC, Noe AJ et al: Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992; 36:830-832
22. Schentag JJ, Watson WA, Nix D, et al: Time dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol 1988; 43:135
23. Product Information: Cipro, ciprofloxacin. Bayer Corporation, West Haven, CT, 2002
24. Harmon SM, Seifert CF: Levothyroxinecholestyramine interaction reemphasized. Ann Intern Med 1991; 115:658-659
25. Neuvonen PJ, Kivisto K, Hirvisalo EL: Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and furosemide. Br J Clin Pharmacol 1988; 25: 229-233
26. Robinson DS, Benjamin DM, McCormick JJ: Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther 1971; 12:491-495
27. Szoka PR, Edgren RA: Drug interactions with oral contraceptives: Compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49(5 Suppl 2): 31S-38S.
28. Davydov L, Yermolnik M, Cuni L: Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37:367-370
29. Bizjak ED, Mauro VF: Digoxin-macrolide drug interaction. Ann Pharmacother 1997; 31:1077-1079
30. Ludden TM: Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10:63-79
31. Rodin SM, Johnson BF: Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15:227-244
32. Greiner B, Eichelbaum M, Fritz P, et al: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-53
33. Eberl S, Renner B, Neubert A, et al: Role of P-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007; 46:1039-1049
34. Jalava KM, Partanen J, Neuvonen P: Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-613
35. Gatmaitan ZC, Arias IM: Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993; 24:77-97
36. Okamura N, Hirai M, Tanigawara Y, et al: Digoxin-cyclosporine A interaction: modulation of the multidrug transporter Pglycoprotein in the kidney. J Pharmacol Exp Ther 1993; 266:1614-1619
37. Egle H, Tritler R, Kummerer K, et al: Linezolid and rifampin: Drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77:451-453
38. Gebhart BC, Barker BC, Markewitz BA: Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-479
39. Dasgupta A, Timmerman TG: In vitro displacement of phenytoin from protein binding by nonsteroidal anti-inflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit 1996; 18:97-99
40. Dasgupta A, Dennen DA, Dean R, et al: Displacement of phenytoin from serum protein carriers by antibiotics: Studies with ceftriaxone, nafcillin, and sulfamethoxazole. Clin Chem 1991; 37:98-100
41. McElnay JC, D'Arcy PF: Displacement of albumin-bound warfarin by anti-inflammatory agents in vitro. Pharm Pharmacol 1980; 32:709-711
42. O'Callaghan JW, Thompson RN, Russel AS: Combining nonsteroidal anti-inflammatory drugs with anticoagulants: Yes and no. Can Med Assoc J 1984; 131:857-858
43. Schafer AI: Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35:209-219
44. Edwards DJ, Lalka D, Cerra F, et al: Alpha1acid glycoprotein concentration and protein binding in trauma. Clin Pharmacol Ther 1982; 31:62-67 (Pubitemid 12135810)
45. Shand DG: Alpha 1-Acid glycoprotein and plasma lidocaine binding. Clin Pharmacokinet 1984; 9(Suppl 1):27-31
46. 1 -acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther 1981; 30: 154-157
47. Landrum Michalets E: Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18:84-112
48. Cheng JWM, Frishman WH, Aronow WS: Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Therapeutics 2009; 16:155-163
49. Zhou SF, Xue CC, Yu XQ, et al: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29:687-710
50. Piancenti FJ: An update and review of antiretroviral therapy. Pharmacotherapy 2006; 26:1111-1133
51. Pai MP, Graci D, Amsden GW: Macrolide drug interactions: An update. Ann Pharmacother 2000; 34:495-513
52. Venkatakrishnan K, von Moltke LL, Greenblat DJ: Effects of antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000; 38:111-180
53. Saad AH, DePestel D, Carver P: Factors influencing the magnitude and clinical significance of drug interactions between azole fungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730-1744
54. Leather HL: Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: What every transplanter needs to know. Bone Marrow Transplant 2004; 33: 137-152
55. Ahonen J, Olkkola KT, Takala A, et al: Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scan 1999; 43:509-514
56. Kress JP, Pohlman A, O'Conner MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-1477
57. Holbrook AM, Pereira JAM, Labiris R, et al: Systemic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095-1106
58. Lu Y, Won KA, Nelson BJ, et al: Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm 2008; 65:947-952
59. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538
60. Tomalik-Scharte D, Lazar A, Fuhr U, et al: The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8:4-15
61. Brockmoller J, Kirchheiner J, Schmider J, et al: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72:438-452
62. Bijl MJ, Visser LE, van Schaik RH, et al: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009; 85:45-50
63. Obase Y, Shimoda, Kawano T: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma Clin Pharmacol Ther 2003; 73:468-474
64. Schentag JJ, Meagher AK, Jellife RW: Aminoglycosides. In: Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Fourth edition. Burton ME, Shaw LM, Schentag JJ, et al (Eds). Baltimore, MD, Lippincott, Williams & Wilkins, 2006, pp 285-327
65. Rea RS, Capitano B: Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007; 28:596-603
66. Huang KC, Wenczak BA, Liu YK: Renal tubular transport of methotrexate in the rhesus monkey and dog. Cancer Res 1979; 39: 4843-4848
67. Cassano WF: Serious methotrexate toxicity caused by interaction with ibuprofen (letter). Am J Pediatr Hematol Oncol 1989; 11:481-482
68. Product Information: Methotrexate LPF, methotrexate. Xanodyne Pharmacal, Florence, KY, 2003
69. Lai MY, Jiang FM, Chung CH, et al: Dose dependent effect of cimetidine on procainamide disposition in man. Int J Clin Pharmacol Ther Toxicol 1988; 26:118-121
70. Bigger JT, Leahey EB: Quinidine and digoxin: an important interaction. Drugs 1982; 24:229-239
71. Kuhlmann J, Dohrmann M, Marcin S: Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. Clin Pharmacol Ther 1986; 39:288-294
72. Product Information: Zosyn, piperacillin so infections in intensive care patients. Crit Care Med 2005; 33:2373-2382
73. Knouss RF, Gebhart RE, Thyrum PT, et al: Variation in quinidine excretion with changing urine pH. Ann Intern Med 1969; 68:1157
74. Gerhardt RE, Knouss RF, Thyrum PT, et al: Quinidine excretion in aciduria and alkaluria. Ann Intern Med 1969; 71:927-933
75. Kopp BJ, Erstad BL, Allen ME, et al: Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection. Crit Care Med 2006; 34:415-425
76. Krishnan V, Murray P: Pharmacologic issues in the critically ill. Clin Chest Med 2003; 24:671-688
77. Smithburger PL, Kane-Gill SL, Benedict NJ, et al: Significance of drug-drug interactions in cardiac intensive care units. Crit Care Med 2009; 37(12):A460
78. Kulmatycki KM, Jamali F: Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci 2005; 8:602-625
79. Renton KW: Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004; 5:235-243
80. Kraemer MJ, Furukawa CT, Kemp JR, et al: Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476-480
81. Chang KC, Bell TD, Lawer BA: Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; I:1132-1133
82. McKindley DS, Hanes SD, Boucher BA: Heptaic drug metabolism in critical illness. Pharmacotherapy 1998; 18:759-778
83. Carcillo JA, Doughty L, Kofos D, et al: Cytochrome P-450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29:980-984
84. LaPointe NMA, Curtis LH, Chan KA, et al: Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006; 15:361-368
85. Pacher P, Ungvari Z, Nanasi PP, et al: Speculations on difference between tricyclic and selective serotonin reuptake inhibitor and antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999; 6: 469-480
86. Kang J, Wang L, Chen XL, et al: Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122-126
87. Viskin S, Justo D, Halkin A, et al: Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45:415-427
88. Ray WA, Murray KT, Meredith S, et al: Oral erythromycin and the risk of sudden cardiac death from cardiac causes. N Eng J Med 2004; 351:1089-1096
89. Faggiano P, Gardini A, D'Aloia A, et al: Torsade de pointes occurring early during oral amiodarone treatment. Int J Cardiol 1996; 55:205-208
90. Marill KA, Runge T: Meta-analysis of the risk of torsades de pointes in patients treated with intravenous racemic sotalol. Acad Emerg Med 2001; 8:117-124
91. Product Information: Avelox, moxifloxacin hydrochloride. Bayer Health Care, West Haven, CT, 2008
92. Keivanidou A, Arnaoutoglou C, Krommydas A, et al: Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J 2009; 16:172-174
93. Kao LW, Furbee RB: Drug-induced QT prolongation. Med Clin North Am 1995; 89: 1125-1144
94. Deitch EA, Saraswati DD: Intensive care unit management of the trauma patient. Crit Care Med 2006; 34:2294-2301
95. Iribarren JL, Jimenez JJ, Hernandez D, et al: Postoperative bleeding in cardiac surgery. Anesthesiology 2008; 108:596-602
96. Sesler JM: Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care 2007; 18:119-28
97. Opatrny L, Delaney JAC, Suissa S: Gastrointestinal haemorrhage risks of selective serotonin receptor antagonist therapy: A new look. Br J Clin Pharmacol 2008; 66:76-81
98. Targownik LE, Bolton JM, Metge CJ, et al: Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104:1475-1482
99. Hulot JS, Bura A, Villard E, et al: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244-2247
100. Barada K, Karrowni W, Abdallah M, et al: Upper gastrointestinal bleeding in patients with acute coronary syndromes: Clinical predictors and prophylactic role of proton pump inhibitors. J Clin Gastroenterol 2008; 42:368-372
101. Gillard M, Arnaud B, Cornily JC, et al: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-260
102. Ho PM, Maddox TM, Wang L, et al: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromes. JAMA 2009; 301:937-944
103. Pezalla E: Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JAm Coll Cardiol 2008; 52:1038-1039
104. Juurlink DN, Gomes T, Kop DT, et al: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180:713-8
105. Salgado CD, O'Grady N, Farr BM: Prevention and control of antimicrobial resistant infections in intensive care patients. Crit Care Med 2005; 33:2373-2382
106. Pai MP, Mammary KM, Rodvold KA: Antibiotic drug interactions. Med Clin North Am 2006; 90:1223-55
107. Marty FM, Lowry CM, Cutler CS, et al: Voriconazole and sirolimus co-administration after allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552-559
108. Osowski CL, Dix SP, Lin LS, et al: Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61:1268-1272
109. Saari TI, Laine K, Bertilsson L, et al: Effect of voriconazole and fluconazole in the pharmacokinetics of intravenous fentanyl. Eur Clin J Pharmacol 2008; 64:25-30
110. * 10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006; 26:135-142
111. Jung SM, Kin KA, Cho HK, et al: Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005; 78:520-528
112. Saari TI, Laine K, Leino K, et al: Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006; 79: 362-370
113. Huang V, Gortney JS: Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 26:1784-1793
114. Young DS. Effects of drugs on laboratory tests. Fourth Edition. Washington, DC, AACC Press, 1995
115. Dunlop DG: Drug-laboratory test interferences: Blood, serum, plasma chemistry; urine tests; hematology. Handbook of Clinical Drug Data. Tenth Edition.
116. Forman DT, Young DS: Drug interference in laboratory testing. Ann Clin Lab Sci 1975; 6:263-271
117. Hansen JL, Schneiweiss FN: Drug interference with laboratory value interpretation: A review. Am J Med Technol 1981; 47:183-7
118. Routh JI, Paul WD: Assessment of interference by aspirin with some assays commonly done in the clinical laboratory. Clin Chem 1976; 22:837-42
119. Sher PP: Drug interferences with clinical laboratory tests. Drugs 1982; 24:24-63
120. Young DS. Effects of drugs on clinical laboratory tests. Fifth Edition. Washington, DC, AACC Press, 2000
121. Hyneck ML, Beradi RR, Johnson RM: Interference of cephalosporins and cefoxitin with serum creatinine determination. Am J Health Syst Pharm 1981; 38:1348-132
122. Grotsch H, Hajdu P: Interference by the new antibiotic cefpirome and other cephalosporins in clinical laboratory tests, with special regard to the "Jaffe" reaction. J Clin Chem Clin Biochem 1987; 25:49-52
123. Saah AJ, Koch TR, Drusano GL: Cefoxitin falsely elevated creatinine levels. JAMA 1982; 247:205-206
124. Lognard M, Cavalier E, Chapelle JP, et al: Acetylcysteine and enzymatic creatinine: Beware of laboratory artifact! Intensive Care Medicine 2008; 34:973-974
125. Murphy JL, Hurt TL, Griswp WR, et al: Interference with creatinine concentration measurement by high dose furosemide infusion. Crit Care Med 1989; 17: 889-890
126. Bartholomew JR, Hursting MJ: Transitioning from argatroban to warfarin in heparininduced thrombocytopenia: An analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005; 19:183-188
127. Walenga JM, Fasanella AR, Iqbal O, et al: Coagulation laboratory testing in patients treated with argatroban. Semin Thomb Hemost 1999; 25(Suppl 1):61-66
128. Webster PS, Oleson FB, Paterson DL, et al: Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/ international normalized ratio results. Blood Coag Fibrinol 2008; 19:32-38
129. Kailajarvi M, Takala T, Gronroos P, et al: Reminders of drug effects on laboratory test results. Clin Chemistry 2000; 46: 1395-1400
130. Hansten PD: Drug interactions. Clinical significance of drug-drug interactions and drug effects on clinical laboratory results. Fifth Edition. Philadelphia, PA, Lea & Fabiger, 1985, pp 460
131. Salway JG: Drug-test interactions handbook. First Edition. London, UK, Chapman and Hall Medical, 1990, pp 1087
132. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet 2007; 370:185-191